POXEL
Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. They believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of th... ose diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).
POXEL
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
2009-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.poxelpharma.com
Total Employee:
11+
Status:
Active
Contact:
+33144719855
Total Funding:
162.9 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF SSL By Default Apple Mobile Web Clips Icon Google Font API DNSSEC Content Delivery Network Amazon LetsEncrypt
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Advisors List
Board_member
2016-04-01
Current Employees Featured
David E. Moller Chief Scientific Officer @ Poxel
Chief Scientific Officer
2020-01-01
Sophie Bozec Senior Vice President, R&D Pharmacology, Co-Founder @ Poxel
Senior Vice President, R&D Pharmacology, Co-Founder
Pascale Fouqueray Executive Vice President, Early Development and Translational Medicine, Co-Founder @ Poxel
Executive Vice President, Early Development and Translational Medicine, Co-Founder
2009-01-01
Elizabeth Woo SVP, Investor Relations, Public Relations & Corporate Communications @ Poxel
SVP, Investor Relations, Public Relations & Corporate Communications
2021-08-01
Christophe Arbet-Engels Chief Medical Officer, Executive Vice President, Late Development & Medical Affairs @ Poxel
Chief Medical Officer, Executive Vice President, Late Development & Medical Affairs
2017-01-01
Thomas Kuhn Chief Executive Officer, Co-Founder @ Poxel
Chief Executive Officer, Co-Founder
2009-01-01
Sébastien Bolze Executive Vice President, Non Clinical Development, Co-Founder @ Poxel
Executive Vice President, Non Clinical Development, Co-Founder
Anne Renevot Chief Financial Officer @ Poxel
Chief Financial Officer
2017-05-01
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Post-IPO Debt - Poxel
IRIS Capital Investment
IRIS Capital Investment investment in Post-IPO Equity - Poxel
IPF Partners
IPF Partners investment in Post-IPO Debt - Poxel
IRIS Capital Investment
IRIS Capital Investment investment in Post-IPO Equity - Poxel
Kreos Capital
Kreos Capital investment in Series B - Poxel
Andera Partners
Andera Partners investment in Series B - Poxel
Bpifrance
Bpifrance investment in Series B - Poxel
InnoBio Fund
InnoBio Fund investment in Series B - Poxel
Omnes Capital
Omnes Capital investment in Series B - Poxel
Andera Partners
Andera Partners investment in Series B - Poxel
Key Employee Changes
Official Site Inspections
http://www.poxelpharma.com Semrush global rank: 3.25 M Semrush visits lastest month: 4.88 K
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Poxel"
Poxel - Crunchbase Company Profile & Funding
Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic …See details»
Poxel S.A. (EPA:POXEL) Company Profile & Overview
Mar 14, 2025 Company profile for Poxel S.A. (EPA:POXEL) with a description, list of executives, contact details and other key facts.See details»
poxelpharma.com Reviews: Is this site a scam or legit?
Is poxelpharma.com legit or a scam? Read reviews, company details, technical analysis, and more to help you decide if this site is trustworthy or fraudulent.See details»
Poxel SA
Robust metabolic pipelineu000bfocused on NASH and rare metabolic diseases Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met …See details»
Poxel S.A. (LON: 0RA2) Company Profile & Overview - Stock Analysis
Jul 11, 2022 Company profile for Poxel S.A. (LON: 0RA2) with a description, list of executives, contact details and other key facts.See details»
POXEL - LinkedIn
Oct 3, 2024 POXEL | 4,713 followers on LinkedIn. Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic …See details»
Poxel Announces Completion of Arbitration with Merck Serono
For more information, please visit: www.poxelpharma.com. In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March …See details»
Poxel and Sumitomo Dainippon Pharma Announce the Approval …
For more information, please visit: www.poxelpharma.com In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March …See details»
Poxel Announces Additional Positive Phase 2a Results, and Phase …
For more information, please visit: www.poxelpharma.com. In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March …See details»
Poxel Announces Financial Calendar for 2022 - ir.poxelpharma.com
LYON, France-- (BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with …See details»
Poxel Announces the Approval of a Prospectus for the Listing of …
Jun 30, 2023 Copies of the Prospectus are available free of charge on the website of the Company ( www.poxelpharma.com) and the AMF ( www.amf-france.org) and at the registered …See details»
Poxel Announces New Strategic Direction with Increasing Focus …
LYON, France-- (BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious …See details»
Poxel Announces Submission of Imeglimin Japanese New Drug …
For more information, please visit: www.poxelpharma.com . In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March …See details»
Poxel Provides Corporate Update and Reports Cash and Revenue …
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, …See details»
Poxel Presents Phase 1b Clinical Results for PXL065 and New …
For more information, please visit: www.poxelpharma.com . In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March …See details»
Poxel Announces Positive Results from a Preclinical Study for …
2 days ago LYON, France, March 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative …See details»
Poxel and Sumitomo Dainippon Pharma Announce Initiation of …
Imeglimin is the first clinical candidate in a new chemical class of oral agents called Glimins by the World Health Organization. Imeglimin has a unique mechanism of action (“MOA”) that targets …See details»
Poxel Provides Corporate Update and Reports Cash and Revenue …
LYON, France-- (BUSINESS WIRE)-- POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious …See details»
Poxel Reports Financial Results for Full Year 2022 and Provides ...
“This past September marked the anniversary of the first year of commercialization of TWYMEEG, our first approved drug, for type-2-diabetes patients in Japan. We have observed a strong …See details»
Poxel Announces Positive Results From Phase 2a NASH Trial With …
For more information, please visit: www.poxelpharma.com. In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March …See details»